Ordering Recommendation
May be useful in confirming a diagnosis of primary biliary cholangitis.
Mnemonic
Methodology
Semi-Quantitative Enzyme-Linked Immunosorbent Assay
Performed
Sun-Sat
Reported
Within 24 hours
New York DOH Approval Status
Specimen Required
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Refrigerated.
Plasma. Contaminated, hemolyzed, grossly icteric, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference Interval
20.0 Units or less | Negative |
20.1-24.9 Units | Equivocal |
25.0 Units or greater | Positive |
Interpretive Data
Anti-mitochondrial antibodies (AMA) are thought to be present in 90-95% of patients with primary biliary cholangitis (PBC). However, the frequency of detected antibodies may be cohort or assay dependent, as lower sensitivities have been reported. Not all PBC patients are positive for AMA; some patients may be positive for SP100 and/or GP210 antibodies. A negative result does not rule out PBC.
FDA
Note
Hotline History
CPT Codes
86381
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0050065 | Mitochondrial (M2) Antibody, IgG | 14251-3 |
Aliases
- AMA
- Anti-Mitochondrial Antibody
- Antibodies to Microtubule Associated Protein 2
- Antimitochondrial Antibodies
- Immunology Profile (AMA)
- Mitochondrial Antibodies, Serum